Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 795-804

  Hofmann, Carmen ^a   Buttenschoen, Klaus ^a   Straeter, Joern ^a   Henne Bruns, Doris ^a   Kornmann, Marko ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Colorectal cancer; Liver metastases; Regional chemotherapy; Tumor colony forming assay

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; COLON CANCER; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; EVALUATION; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INCUBATION TIME; LIVER METASTASIS; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HEPATIC ARTERY; HT29 CELLS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; TUMOR STEM CELLS;

EID: 17444417866     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
2. Garcia-Carbonero R and Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8: 641-661, 2002.
3. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G and Sparreboom A: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001.
4. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M: Antitumor activity of 7-ethyl-10-[4-(1- piperidino)-1-piperidino]carbonyloxy-camptothec, in a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 57: 4187-4191, 1991.
6. Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W and Larsson R: Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer 36: 2120-2127, 2000.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 555: 1041-1047, 2000.
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
9. Bismuth H and Adam R: Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 25(2 Suppl 5): 40-46, 1998.
10. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 55: 5-26, 2003.
11. Cohen AD and Kemeny NE: An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8: 553-566, 2003.
12. Link KH, Leder G, Pillasch J, Butzer U, Staib L, Kornmann M, Bruckner U and Beger HG: In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol 14: 189-201, 1998.
13. Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G, Formentini A, Staib L, Pillasch J and Beger HG: Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer 92: 2746-2753, 2001.
14. Link KH, Kornmann M, Leder GH, Butzer U, Pillasch J, Staib L, Gansauge F and Beger HG: Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial. Clin Cancer Res 2: 1469-1474, 1996.
15. Kornmann M, Arber N and Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352, 1998.
16. Kornmann M, Tangvoranuntakul P and Korc M: TGF-beta-1 up-regulates cyclin D1 expression in COLO-357 cells, whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor. Int J Cancer 83: 247-254, 1999.
17. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S and Rustum YM: Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19: 1501-1518, 2001.
18. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77: 1254-1262, 1996.
19. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL and Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10: 663-666, 1999.
20. Kornmann M, Fakler H, Butzer U, Beger HG and Link KH: Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res 20: 3259-3264, 2000.
21. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H and Kornmann M: Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 23: 5203-5208, 2003.
22. Calvo E, Cortes J, Gonzalez-Cao M, Rodriguez J, Aramendia JM, Fernandez-Hidalgo O, Martin-Algarra S, Salgado JE, Martinez-Monge R, de Irala J and Brugarolas A: Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer, a feasibility pilot study. Oncology 63: 254-265, 2002.
23. Yamaguchi T, Mori T, Takahashi K, Ohue M, Homma S, Arai K, Iwasaki Y and Rimura Y: Hepatic arterial infusion with irinotecan for the colorectal cancer patient with liver metastasis - a case report. Gan To Kagaku Ryoho 29: 2370-2372, 2002.
24. Fiorentini G, Lucchi SR, Giovanis P, Cantore M, Guadagni S and Papiani G: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: results of a phase I clinical study. Tumori 87: 388-390, 2001.
25. Van Riel JM, van Groeningen CJ, Kedde MA, Gall H, Leisink JM, Gruia G, Pinedo HM, van der Vijgh WJ and Giaccone G: Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 8: 405-412, 2002.
26. Fiorentini G, Rossi S, Dentico P, Bernardeschi P, Calcinai A, Bonechi F, Cantore M, Guadagni S and De Simone M: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 89: 382-384, 2003.
27. Van Ark-Otte J, Kedde MA, Van der Vijgh WJF, Dingemans A-MC, Jansen WJM, Pinedo HM, Boven E and Giaccone G: Determinants of CPT-11 and SN-38 acitivities in human lung cancer cells. Br J Cancer 77: 2171-2176, 1998.
28. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, Selves J, Chatelut E, Bugat R and Canal P: CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer 80: 364-370, 1999.
29. Beger HG, Gansauge F, Buchler MW and Link KH: Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg 23: 946-949, 1999.
30. Link KH, Kornmann M, Butzer U, Leder G, Sunelaitis E, Pillasch J, Salonga D, Danenberg KD, Danenberg PV and Beger HG: Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 89: 288-296, 2000.